MEDIRELIEF ULTRA- menthol patch 
FARLA MEDICAL HEALTHCARE LTD

----------

MediRelief Ultra Strength Menthol 5% Patch

Drug Facts

Active Ingredients & Purpose

Active ingredients (in each patch)

Purpose

Menthol 5%.................................................................................................................................................................

Topical analgesic

Uses

For the temporary relief of minor aches and pains of muscles and joints associated with

Warnings

FOR EXTERNAL USE ONLY. Avoid contact with the eyes.

Do not use

  • on wounds or damaged skin
  • on a tight bandage
  • with a heating pad
  • on sensitive skin
  • if allergic to any ingredients in this product

Stop use and ask a doctor if

  • condition worsens
  • redness is present
  • symptoms persist for more than 7 days or clear up and occur again within a few days

If pregnant of breast-feeding

ask a health professional before use.

KEEP OUT OF REACH OF CHILDREN

If swallowed, get medical help or contact a Poison Control Center right away.

Directions

Other Information

TAMPER EVIDENT: Do not use if pouch containing the patch is torn or broken.

Inactive Ingredients

carboxymethylcellulose, dihydroxyaluminum aminoacetate, glycerin, kaolin, methylparaben, mineral oil, petrolatum, polyacrylic acid, polysorbate 80, povidone, propylene glycol, propylparaben, sodium polyacrylate, tartaric acid, titanium dioxide, water.

Principal Display Panel

(Medium) Patch
NDC 73486-101-25

(Large) Patch
NDC 73486-101-35

Large Patches

Medium Patches

MEDIRELIEF  ULTRA
menthol patch
Product Information
Product TypeHUMAN OTC DRUGItem Code (Source)NDC:73486-101
Route of AdministrationTOPICAL
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
MENTHOL, UNSPECIFIED FORM (UNII: L7T10EIP3A) (MENTHOL, UNSPECIFIED FORM - UNII:L7T10EIP3A) MENTHOL, UNSPECIFIED FORM5 g
Inactive Ingredients
Ingredient NameStrength
GLYCERIN (UNII: PDC6A3C0OX)  
SODIUM POLYACRYLATE (8000 MW) (UNII: 285CYO341L)  
PROPYLPARABEN (UNII: Z8IX2SC1OH)  
PROPYLENE GLYCOL (UNII: 6DC9Q167V3)  
WATER (UNII: 059QF0KO0R)  
DIHYDROXYALUMINUM AMINOACETATE (UNII: DO250MG0W6)  
POVIDONE (UNII: FZ989GH94E)  
METHYLPARABEN (UNII: A2I8C7HI9T)  
KAOLIN (UNII: 24H4NWX5CO)  
POLYSORBATE 80 (UNII: 6OZP39ZG8H)  
POLYACRYLIC ACID (8000 MW) (UNII: 73861X4K5F)  
TITANIUM DIOXIDE (UNII: 15FIX9V2JP)  
TARTARIC ACID (UNII: W4888I119H)  
PETROLATUM (UNII: 4T6H12BN9U)  
CARBOXYMETHYLCELLULOSE (UNII: 05JZI7B19X)  
MINERAL OIL (UNII: T5L8T28FGP)  
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:73486-101-255 in 1 CARTON05/04/2020
11 in 1 POUCH; Type 0: Not a Combination Product
2NDC:73486-101-355 in 1 CARTON05/04/2020
21 in 1 POUCH; Type 0: Not a Combination Product
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
OTC Monograph DrugM01705/04/2020
Labeler - FARLA MEDICAL HEALTHCARE LTD (230061759)

Revised: 2/2024
Document Id: 12194ec2-4161-0f13-e063-6394a90ac438
Set id: a4dea2ad-59e3-306b-e053-2a95a90a56d8
Version: 6
Effective Time: 20240223
 
FARLA MEDICAL HEALTHCARE LTD